General Information of Drug (ID: DMMYZ3D)

Drug Name
Tositumomab
Synonyms Bexxar (TN)
Indication
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Antibody
Sequence
>heavy chain 1
QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY
NQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV
SGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain 1
1QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPA
RFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYP
>heavy chain 2
2QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTS
YNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVT
VSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain 2
2QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPA
RFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNR
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 0.8 hours [2]
Metabolism
The drug is metabolized via opsonization via the reticuloendothelial system []
Cross-matching ID
DrugBank ID
DB00081
TTD ID
D0I2AV

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tositumomab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cilostazol DMZMSCT Major Increased risk of bleeding by the combination of Tositumomab and Cilostazol. Arterial occlusive disease [BD40] [4]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Tositumomab and Roflumilast. Asthma [CA23] [5]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Tositumomab and Pentosan polysulfate. Chronic pain [MG30] [6]
Ketoprofen DMRKXPT Major Increased risk of bleeding by the combination of Tositumomab and Ketoprofen. Chronic pain [MG30] [4]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Tositumomab and Levomilnacipran. Chronic pain [MG30] [7]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Tositumomab and Regorafenib. Colorectal cancer [2B91] [5]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Tositumomab and Ardeparin. Coronary thrombosis [BA43] [4]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Tositumomab and Rivaroxaban. Deep vein thrombosis [BD71] [4]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Tositumomab and Sertraline. Depression [6A70-6A7Z] [7]
Fluoxetine DM3PD2C Moderate Increased risk of bleeding by the combination of Tositumomab and Fluoxetine. Depression [6A70-6A7Z] [7]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Tositumomab and Vilazodone. Depression [6A70-6A7Z] [7]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Tositumomab and Paroxetine. Depression [6A70-6A7Z] [7]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Tositumomab and Vortioxetine. Depression [6A70-6A7Z] [7]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Tositumomab and Duloxetine. Depression [6A70-6A7Z] [7]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Tositumomab and Milnacipran. Depression [6A70-6A7Z] [7]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Tositumomab and Escitalopram. Depression [6A70-6A7Z] [7]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Tositumomab and Desvenlafaxine. Depression [6A70-6A7Z] [7]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Tositumomab and Clomipramine. Depression [6A70-6A7Z] [7]
Fluvoxamine DMQTJSX Moderate Increased risk of bleeding by the combination of Tositumomab and Fluvoxamine. Depression [6A70-6A7Z] [7]
Venlafaxine DMR6QH0 Moderate Increased risk of bleeding by the combination of Tositumomab and Venlafaxine. Depression [6A70-6A7Z] [7]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Tositumomab and Apigenin. Discovery agent [N.A.] [8]
Citalopram derivative 1 DMITX1G Moderate Increased risk of bleeding by the combination of Tositumomab and Citalopram derivative 1. Discovery agent [N.A.] [7]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Tositumomab and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [7]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Tositumomab and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [9]
Mefenamic acid DMK7HFI Major Increased risk of bleeding by the combination of Tositumomab and Mefenamic acid. Female pelvic pain [GA34] [4]
Tazemetostat DMWP1BH Major Increased risk of bleeding by the combination of Tositumomab and Tazemetostat. Follicular lymphoma [2A80] [4]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Tositumomab and Avapritinib. Gastrointestinal stromal tumour [2B5B] [5]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Tositumomab and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Tositumomab and Teriflunomide. Hyper-lipoproteinaemia [5C80] [11]
Dipyridamole DMXY30O Major Increased risk of bleeding by the combination of Tositumomab and Dipyridamole. Hypertension [BA00-BA04] [4]
Meclofenamic acid DM05FXR Major Increased risk of bleeding by the combination of Tositumomab and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [4]
Ticlopidine DMO946V Major Increased risk of bleeding by the combination of Tositumomab and Ticlopidine. Ischaemic/haemorrhagic stroke [8B20] [4]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Tositumomab and Denosumab. Low bone mass disorder [FB83] [12]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Tositumomab and Cladribine. Mature B-cell leukaemia [2A82] [5]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Tositumomab and Alemtuzumab. Mature B-cell leukaemia [2A82] [13]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Tositumomab and Acalabrutinib. Mature B-cell lymphoma [2A85] [14]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Tositumomab and Ibrutinib. Mature B-cell lymphoma [2A85] [15]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Tositumomab and Ponatinib. Mature B-cell lymphoma [2A85] [16]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Tositumomab and Arry-162. Melanoma [2C30] [4]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Tositumomab and LGX818. Melanoma [2C30] [4]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Tositumomab and Tecfidera. Multiple sclerosis [8A40] [17]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Tositumomab and Siponimod. Multiple sclerosis [8A40] [18]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Tositumomab and Fingolimod. Multiple sclerosis [8A40] [19]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Tositumomab and Ocrelizumab. Multiple sclerosis [8A40] [20]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Tositumomab and Ozanimod. Multiple sclerosis [8A40] [5]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Tositumomab and Fedratinib. Myeloproliferative neoplasm [2A20] [4]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Tositumomab and Ruxolitinib. Myeloproliferative neoplasm [2A20] [4]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Tositumomab and Dasatinib. Myeloproliferative neoplasm [2A20] [4]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Tositumomab and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [6]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Tositumomab and Prasugrel. Myocardial infarction [BA41-BA43] [4]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Tositumomab and Vorapaxar. Myocardial infarction [BA41-BA43] [4]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Tositumomab and Tirofiban. Myocardial infarction [BA41-BA43] [4]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Tositumomab and Sibutramine. Obesity [5B80-5B81] [21]
Diclofenac DMPIHLS Major Increased risk of bleeding by the combination of Tositumomab and Diclofenac. Osteoarthritis [FA00-FA05] [4]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Tositumomab and Nepafenac. Osteoarthritis [FA00-FA05] [9]
Naproxen DMZ5RGV Major Increased risk of bleeding by the combination of Tositumomab and Naproxen. Osteoarthritis [FA00-FA05] [4]
Aspirin DM672AH Major Increased risk of bleeding by the combination of Tositumomab and Aspirin. Pain [MG30-MG3Z] [4]
Etodolac DM6WJO9 Major Increased risk of bleeding by the combination of Tositumomab and Etodolac. Pain [MG30-MG3Z] [4]
Diflunisal DM7EN8I Major Increased risk of bleeding by the combination of Tositumomab and Diflunisal. Pain [MG30-MG3Z] [4]
Ibuprofen DM8VCBE Major Increased risk of bleeding by the combination of Tositumomab and Ibuprofen. Pain [MG30-MG3Z] [4]
Nabumetone DMAT2XH Major Increased risk of bleeding by the combination of Tositumomab and Nabumetone. Pain [MG30-MG3Z] [4]
Piroxicam DMTK234 Major Increased risk of bleeding by the combination of Tositumomab and Piroxicam. Pain [MG30-MG3Z] [4]
Ketorolac DMI4EL5 Major Increased risk of bleeding by the combination of Tositumomab and Ketorolac. Postoperative inflammation [1A00-CA43] [4]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Tositumomab and Bromfenac. Postoperative inflammation [1A00-CA43] [9]
Treprostinil DMTIQF3 Major Increased risk of bleeding by the combination of Tositumomab and Treprostinil. Pulmonary hypertension [BB01] [4]
Epoprostenol DMUTYR2 Major Increased risk of bleeding by the combination of Tositumomab and Epoprostenol. Pulmonary hypertension [BB01] [4]
Iloprost DMVPZBE Major Increased risk of bleeding by the combination of Tositumomab and Iloprost. Pulmonary hypertension [BB01] [4]
Meloxicam DM2AR7L Major Increased risk of bleeding by the combination of Tositumomab and Meloxicam. Rheumatoid arthritis [FA20] [4]
Sulindac DM2QHZU Major Increased risk of bleeding by the combination of Tositumomab and Sulindac. Rheumatoid arthritis [FA20] [4]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Tositumomab and Canakinumab. Rheumatoid arthritis [FA20] [22]
Oxaprozin DM9UB0P Major Increased risk of bleeding by the combination of Tositumomab and Oxaprozin. Rheumatoid arthritis [FA20] [4]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Tositumomab and Rilonacept. Rheumatoid arthritis [FA20] [22]
Flurbiprofen DMGN4BY Major Increased risk of bleeding by the combination of Tositumomab and Flurbiprofen. Rheumatoid arthritis [FA20] [4]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Tositumomab and Golimumab. Rheumatoid arthritis [FA20] [23]
Fenoprofen DML5VQ0 Major Increased risk of bleeding by the combination of Tositumomab and Fenoprofen. Rheumatoid arthritis [FA20] [4]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Tositumomab and Leflunomide. Rheumatoid arthritis [FA20] [11]
Indomethacin DMSC4A7 Major Increased risk of bleeding by the combination of Tositumomab and Indomethacin. Rheumatoid arthritis [FA20] [4]
Tolmetin DMWUIJE Major Increased risk of bleeding by the combination of Tositumomab and Tolmetin. Rheumatoid arthritis [FA20] [4]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Tositumomab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [24]
Warfarin DMJYCVW Major Increased risk of bleeding by the combination of Tositumomab and Warfarin. Supraventricular tachyarrhythmia [BC81] [4]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Tositumomab and Caplacizumab. Thrombocytopenia [3B64] [4]
Anagrelide DMSQ8MD Major Increased risk of bleeding by the combination of Tositumomab and Anagrelide. Thrombocytosis [3B63] [4]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Tositumomab and Apixaban. Thrombosis [DB61-GB90] [4]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Tositumomab and Cangrelor. Thrombosis [DB61-GB90] [4]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Tositumomab and Brilinta. Thrombosis [DB61-GB90] [5]
Argatroban DMFI46A Major Increased risk of bleeding by the combination of Tositumomab and Argatroban. Thrombosis [DB61-GB90] [4]
Clopidogrel DMOL54H Major Increased risk of bleeding by the combination of Tositumomab and Clopidogrel. Thrombosis [DB61-GB90] [4]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Tositumomab and Cabozantinib. Thyroid cancer [2D10] [25]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Tositumomab and Azathioprine. Transplant rejection [NE84] [18]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Tositumomab and Betrixaban. Venous thromboembolism [BD72] [4]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Tositumomab and Ganciclovir. Virus infection [1A24-1D9Z] [18]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Tositumomab and Valganciclovir. Virus infection [1A24-1D9Z] [18]
⏷ Show the Full List of 92 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6781).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
4 Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab). GlaxoSmithKline, Research Triangle Park, NC.
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
7 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
8 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
9 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
10 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
11 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
12 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
13 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
14 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
15 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
16 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
17 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
18 Cerner Multum, Inc. "Australian Product Information.".
19 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
21 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
22 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
23 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
24 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
25 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.